TOSITUMOMAB I-131: 38 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
38
Total FAERS Reports
29 (76.3%)
Deaths Reported
3
Hospitalizations
38
As Primary/Secondary Suspect
2
Life-Threatening
First Report: 20171017 · Latest Report: 20220805
What Are the Most Common TOSITUMOMAB I-131 Side Effects?
#1 Most Reported
Second primary malignancy
22 reports (57.9%)
#2 Most Reported
Myelodysplastic syndrome
6 reports (15.8%)
#3 Most Reported
Neoplasm malignant
5 reports (13.2%)
All TOSITUMOMAB I-131 Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Second primary malignancy | 22 | 57.9% | 21 | 0 |
| Myelodysplastic syndrome | 6 | 15.8% | 0 | 2 |
| Neoplasm malignant | 5 | 13.2% | 5 | 0 |
Who Reports TOSITUMOMAB I-131 Side Effects? Age & Gender Data
Gender: 11.1% female, 88.9% male. Average age: 66.2 years. Most reports from: US. View detailed demographics →
Is TOSITUMOMAB I-131 Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2017 | 2 | 0 | 0 |
| 2022 | 1 | 0 | 1 |
What Is TOSITUMOMAB I-131 Used For?
| Indication | Reports |
|---|---|
| B-cell lymphoma | 19 |
| Follicle centre lymphoma, follicular grade i, ii, iii | 10 |
| Mantle cell lymphoma stage iv | 5 |
Official FDA Label for TOSITUMOMAB I-131
Official prescribing information from the FDA-approved drug label.